World Bispecific and T-Cell Engager Summit South Korea

Memo

Bispecifics and T-cell engagers are redefining the future of solid tumor treatment. With the landmark approvals of tarlatamab and ivonescimab, the spotlight is firmly on these modalities as powerful solutions for long-standing unmet needs. At the same time, the field is rapidly evolving beyond first-generation designs, with innovations in co-stimulation, conditional activation, multispecific engineering, and affinity tuning aimed at deepening response rates while mitigating dose-limiting toxicities. Innovation is rife within Korea, with companies such as ABL Bio, Novelty Nobility, ABION, and IM Biologics capturing international attention and investment, positioning Korea as a key player in the bispecific and TCE revolution. To accelerate this momentum, the inaugural World Bispecific and T-Cell Engager Summit South Korea comes as the only event in Asia dedicated to bringing together biopharma professionals focused on the discovery and development of differentiated Bispecifics and T-cell engagers that could become first-in-class therapies. Featuring key international opinion leaders, the agenda will deep dive into co-stimulation techniques, conditional activation, affinity window engineering, and bispecific ADCs (bsADCs), spotlighting cutting-edge strategies to expand the therapeutic window, overcome antigen escape, reduce CRS, and improve clinical predictability. As part of the World Targeted Therapeutics Summit South Korea, organized by Hanson Wade, this is your opportunity to converge with peers working on antibody-drug conjugates (ADCs), targeted protein degradation, and induced proximity, which aim to turn South Korea into the next global hub for biopharma innovation in targeted therapeutics. From discovery to manufacturing, you'll get end-to-end coverage to equip your entire team with the insights needed to innovate and differentiate, ultimately attract interest for global pharma partnerships. URLs:Tickets: https://go.evvnt.com/3521884-2?pid=5569Brochure: https://go.evvnt.com/3521884-3?pid=5569 Prices:Drug Developer Pricing - 3 Day Pass (Workshop Day + Conference): USD 2548.00,Drug Developer Pricing - 2 Day Pass (Conference Only): USD 1849.00,Academic Pricing - 3 Day Pass (Workshop Day + Conference): USD 2298.00,Academic Pricing - 2 Day Pass (Conference Only): USD 1649.00,Service Provider Pricing - 3 Day Pass (Workshop Day + Conference): USD 5198.00,Service Provider Pricing - 2 Day Pass (Conference Only): USD 3899.00 Speakers: Aaron Sato, Chief Strategy Officer, Adimab, JJ You, Vice President, Antibody Discovery, AP Biosciences, Saso Cemerski, Executive Director, Head of Immune Engagers, AstraZeneca, Bin Zou, Founder and Chief Executive Officer, Axcynsis, Longli Zhou, Senior Researcher, Beacon by Hanson Wade, Mingjiu Chen, Founder, Chairman and Chief Executive Officer, Biosion, Leticia Corrales, Laboratory Head, Boehringer Ingelheim, Shumin Liu, President, Enduring Biotech, Ertan Eryilmaz, Vice President, Biologics, InduPro, Katsuaki Usami, Principal Investigator, Innovation Center, Kyowa Kirin, David DiLillo, Executive Director, Immune-Oncology, Regeneron, Nitin Damle, Executive Vice President and Chief Innovation Officer, Sun Pharma, Jing Li, Chief Executive Officer, VelaVigo, Alexey Berezhnoy, Director, Immunology, Zymeworks, Sangmi Lee, Clinical Development Head, ABL Bio, Jinwon Jung, Senior Director, ABL Bio, Chris Kim, Chief Executive Officer, CelleMEDY, Manheum Na, Head, New Biological Drug Department, Celltrion, Nari Yun, Chief Development Officer, GI Innovation, Young Su Noh, Director, Head of Clinical Research and Development, Hanmi Pharm, Jin-San Yoo, President, R and D, PharmAbcine, WonGyun Ahn, Associate Director, Qurient, Shawn Seong, Chief Executive Officer, Shaperon Category: Conferences | Science, Health and Medicine | Pharmaceuticals Date and Time: 9th June 2026 at 8:00 am to 11th June 2026 at 4:30 pm Venue details: COEX Magok Le West, 143 Magokjungang-ro, Gangseo-gu, Seoul, Korea (South)